Global Asherman’s Syndrome Market – Industry Trends and Forecast to 2030

Global Asherman’s Syndrome Market, By Diagnosis (Hysterosalpingography, Hysterosonogram, Ultrasound, and Others), Treatment (Surgery, Hysteroscopy, Antibiotics, and Others), Dosage Forms (Tablet, Injections, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2030.

Asherman’s Syndrome Market Analysis and Size

As per the International Asherman's Association, dilatation and curettage (D and C) procedures cause almost 90% of all instances of Asherman syndrome. Following an incomplete miscarriage, a retained placenta after birth, or an elective abortion, a D and C are usually performed. Asherman's Syndrome (AS) is an acquired disorder characterized by intrauterine adhesions (IUA), which produce symptoms such as irregular menstruation, pelvic pain, infertility, recurrent miscarriage, aberrant placentation, and psychological anguish. AS is traditionally thought to be an iatrogenic condition caused by trauma to the pregnant uterus. Different conditions can cause endometrium deterioration, altering the endometrial stem cell niche and resulting in IUAs.

Data Bridge Market Research analyses that the global asherman’s syndrome market which was USD 247.33 million in 2022, would rocket up to USD 412.42 million by 2030, and is expected to undergo a CAGR of 6.6% during the forecast period. This indicates the market value. “Antibiotics” is expected to dominate the treatment segment of the global asherman’s syndrome market owing to the growing demand for better methods for treatment in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asherman’s Syndrome Market Scope and Segmentation

Market Definition

Asherman's syndrome is a rare, acquired disorder in which scar tissue develops in the uterus or cervix. The uterine walls thicken as a result of the scar tissue, reducing the size of the uterus and, in severe cases, fusing the walls. The adhesions or scar tissue are cut and removed during surgery. Hysteroscopy is frequently used to accomplish this. Small devices and a camera are inserted via the cervix into the uterus. Asherman's syndrome is also termed intrauterine adhesions (IUA).

Global Asherman’s Syndrome Market Dynamics

Drivers

• Rise in the Number of Cases of Asherman’s Syndrome

The surging number of cases of Asherman’s syndrome is a major factor driving the market's growth rate during the forecast period of 2022-2029. Asherman syndrome is a rather uncommon disorder. It mostly affects women who have had many dilation and curettage (D and C) surgeries. Asherman syndrome can also be caused by a severe pelvic infection that is unrelated to surgery. Adhesions in the uterine cavity can also develop following tuberculosis or schistosomiasis infection. In the United States, these infections are uncommon. Even fewer women experience uterine problems as a result of these infections.

• Increasing Investment in Healthcare Infrastructure

Another significant factor influencing the growth rate of Asherman’s syndrome market is the rising healthcare expenditure, which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, and this will further influence the market dynamics.

• Growing Incidences of Endometriosis

The rising incidences of endometriosis is estimated to enhance the market’s growth rate. Endometriosis, a common inflammatory disease, causes Asherman's syndrome. It's caused by a uterine tissue (endometrium) build-up that can't be shed before menstruation. Lower back or thigh pain, as well as severe pain throughout the menstrual cycle, are possible symptoms.

Opportunities

• Increased Awareness and Diagnosis

Asherman's Syndrome is often underdiagnosed or misdiagnosed, leading to delayed treatment and management. There is an opportunity to raise awareness about the condition among both healthcare professionals and patients. By educating healthcare professionals about the signs, symptoms, and diagnostic approaches for Asherman's Syndrome, more accurate and timely diagnoses can be made. Additionally, creating awareness among women about the condition and its potential impact on fertility and reproductive health can encourage them to seek medical help and receive appropriate treatment.

• Development of Novel Treatment Options

Currently, the mainstay of treatment for Asherman's Syndrome is hysteroscopic surgery to remove adhesions and restore the normal uterine cavity. However, there is a need for additional treatment options, especially for cases with severe adhesions or recurrent disease. Research and development efforts can explore novel therapeutic approaches, such as regenerative medicine techniques, stem cell therapy, and targeted drug delivery systems, to promote tissue regeneration and prevent adhesion recurrence.

Restraints/Challenges

• Underdiagnosis and Misdiagnosis

Asherman's syndrome is often underdiagnosed or misdiagnosed, leading to delayed or ineffective treatment. The lack of awareness among healthcare professionals about the condition and its symptoms can contribute to this challenge. Improving awareness and education among healthcare professionals is crucial to ensure timely and accurate diagnoses.

• Limited Treatment Options

The current treatment for asherman's syndrome primarily involves hysteroscopic surgery to remove adhesions. However, the success rate of this procedure can vary depending on the severity and location of the adhesions. In cases of severe adhesions or recurrent disease, treatment options may be limited, and the chances of achieving a successful pregnancy may be reduced. There is a need for further research and development to explore alternative and more effective treatment options for Asherman's Syndrome.

This global asherman’s syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asherman’s Syndrome market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

Global Asherman’s Syndrome Market Scope

The global asherman’s syndrome market is segmented on the basis of diagnosis, treatment, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Hysterosalpingography
• Hysterosonogram
• Ultrasound
• Others

Treatment

• Surgery
• Hysteroscopy
• Antibiotics
• Others

Dosage Forms

• Tablet
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Asherman’s Syndrome Market Regional Analysis/Insights

The global asherman’s syndrome market is analysed, and market size insights and trends are provided by country, diagnosis, treatment, dosage forms, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global asherman’s syndrome market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.

North America is expected to dominate the global asherman’s syndrome market because of the growing prevalence of asherman’s syndrome, and rising healthcare expenditure will further propel the market’s growth rate in this region. In addition, the growing presence of major key players will further propel the market’s growth rate in this region.  

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data. 

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global asherman’s syndrome market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global asherman’s syndrome market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global asherman’s syndrome market.

Competitive Landscape and Asherman’s Syndrome Market Share Analysis

The global asherman’s syndrome market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global asherman’s syndrome market.

Some of the major players operating in the global asherman’s syndrome market are:

•  Allergan (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Merck KGaA (Germany)
• Melinta Therapeutics LLC (U.S.)
• Basilea Pharmaceutica Ltd. (Switzerland)
• Tetraphase Pharmaceuticals (U.S.)
• Paratek Pharmaceuticals, Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Abbott (U.S.)